Managing cardiovascular risk factors: trial evidence in women.
Cardiovascular disease remains by far the leading cause of death for women worldwide. Despite a large body of research identifying effective interventions to reduce cardiovascular risk, translation into practice has been slow. This review pinpoints areas in particular need of improvement and summarizes gender-specific analyses in recent randomized trials assessing the impact of risk factor modulation on cardiovascular events.
Hsia
J
J
AstraZeneca LP, 1800 Concord Pike, PO Box 15437, Wilmington, DE 19850-5437, USA. judith.hsia@astrazeneca.com
D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000150:complications / Q000453:epidemiology* / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000628:therapy; D003925:Diabetic Angiopathies / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000517:prevention & control / Q000628:therapy; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D016387:Women's Health
D015415:Biomarkers; D002097:C-Reactive Protein